URL https://seer.cancer.gov/ [accessed on 31, 2017. ,
Age as a prognostic factor in the malignant melanoma population, Annals of Surgical Oncology, vol.218, issue.6, pp.487-94, 1994. ,
DOI : 10.1093/ajcp/74.3.247
Correlation Between Prognostic Factors and Increasing Age in Melanoma, Annals of Surgical Oncology, vol.86, issue.(9 Suppl), pp.259-64, 2004. ,
DOI : 10.1245/ASO.2004.04.015
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, issue.9992, pp.444-51, 2015. ,
DOI : 10.1016/S0140-6736(15)60898-4
Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009. ,
DOI : 10.1200/JCO.2009.23.4799
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035/pdf
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients, Clinica Chimica Acta, vol.470, pp.8-13, 2017. ,
DOI : 10.1016/j.cca.2017.04.009
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma, Clinica Chimica Acta, vol.472 ,
DOI : 10.1016/j.cca.2017.07.012
-Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014. ,
DOI : 10.1056/NEJMoa1408868
Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, issue.17, pp.4449-58, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0887
URL : http://clincancerres.aacrjournals.org/content/clincanres/20/17/4449.full.pdf
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites, The Journal of Clinical Pharmacology, vol.12, issue.Suppl. 1, pp.696-706, 2014. ,
DOI : 10.2174/138920011796504527
Population pharmacokinetics and exposure???response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma, Cancer Chemotherapy and Pharmacology, vol.45, issue.2 ,
DOI : 10.1016/j.ejca.2008.10.026
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014. ,
DOI : 10.1016/S1470-2045(14)70012-9
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.26, pp.3205-3216, 2013. ,
DOI : 10.1200/JCO.2013.49.8691
Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma, Melanoma Research, vol.24, issue.5, pp.468-74, 2014. ,
DOI : 10.1097/CMR.0000000000000110
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, The Lancet Oncology, vol.15, issue.4, pp.436-480, 2014. ,
DOI : 10.1016/S1470-2045(14)70051-8
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015. ,
DOI : 10.1056/NEJMoa1412690
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, British Journal of Dermatology, vol.230, issue.Suppl., pp.1153-60, 2012. ,
DOI : 10.1006/bbrc.1996.5891
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem, Current Oncology Reports, vol.365, issue.15, pp.249-59, 2013. ,
DOI : 10.1074/jbc.273.34.21730
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions, International Journal of Dermatology, vol.163, issue.3, pp.376-84, 2014. ,
DOI : 10.1111/j.1365-2133.2010.09751.x
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF, Cell, vol.140, issue.2, pp.209-230, 2010. ,
DOI : 10.1016/j.cell.2009.12.040
URL : https://doi.org/10.1016/j.cell.2009.12.040
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.50, issue.7287, pp.431-436, 2010. ,
DOI : 10.1128/MCB.14.12.8212
Medication Non-Adherence in the Elderly, Drugs & Aging, vol.15, issue.12, pp.793-811, 2004. ,
DOI : 10.2165/00002512-200421120-00004
Medication Adherence in Older Adults With Cognitive Impairment: A Systematic Evidence-Based Review, The American Journal of Geriatric Pharmacotherapy, vol.10, issue.3, pp.165-77, 2012. ,
DOI : 10.1016/j.amjopharm.2012.04.004
Polypharmacy and potentially inappropriate medication use in geriatric oncology, Journal of Geriatric Oncology, vol.7, issue.5, pp.346-53, 2016. ,
DOI : 10.1016/j.jgo.2016.07.010
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037024/pdf
A Systematic Review of Adherence to Oral Antineoplastic Therapies, The Oncologist, vol.21, issue.3, pp.354-76, 2016. ,
DOI : 10.1634/theoncologist.2015-0405
Determinants of patient adherence: a review of systematic reviews, Frontiers in Pharmacology, vol.4, p.91, 2013. ,
DOI : 10.3389/fphar.2013.00091
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine, Annals of Oncology, vol.25, issue.7, pp.1428-1464, 2014. ,
DOI : 10.1093/annonc/mdu154
Boulogne-Billancourt: Collec-tion état des lieux et des connaissances, ouvrage collectif éditépar l'INCa, 2013. ,
Cancer incidence and mortality in France over the 1980???2012 period: Solid tumors, Revue d'??pid??miologie et de Sant?? Publique, vol.62, issue.2, pp.95-108, 2014. ,
DOI : 10.1016/j.respe.2013.11.073
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure, European Journal of Cancer, vol.41, issue.1, pp.45-60, 1990. ,
DOI : 10.1016/j.ejca.2004.10.016
MATHEMATICAL MODELS OF AGE AND ULTRAVIOLET EFFECTS ON THE INCIDENCE OF SKIN CANCER AMONG WHITES IN THE UNITED STATES, American Journal of Epidemiology, vol.105, issue.5, pp.420-427, 1977. ,
DOI : 10.1093/oxfordjournals.aje.a112400
Melanoma and sun exposure: An overview of published studies, International Journal of Cancer, vol.52, issue.2, pp.198-203, 1997. ,
DOI : 10.1002/ijc.2910520128
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R/pdf
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin, Pigment Cell & Melanoma Research, vol.65, issue.10, pp.879-97, 2011. ,
DOI : 10.1086/302494
Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based Edifice Melanoma survey, Journal of the European Academy of Dermatology and Venereology, vol.28, issue.Suppl 3, pp.23-30, 2015. ,
DOI : 10.1177/109019810102800304
The genetics of hereditary melanoma and nevi, Cancer, vol.14, issue.S11, pp.2464-77, 1999. ,
DOI : 10.1200/JCO.1996.14.5.1730
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus, Nature Genetics, vol.52, issue.1, pp.23-29, 1994. ,
DOI : 10.1001/jama.269.5.558
CDKN2A (P16INK4a) andCDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas, Genes, Chromosomes and Cancer, vol.12, issue.4, pp.339-387, 1999. ,
DOI : 10.1038/bjc.1996.460
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas, Science, vol.35, issue.suppl_1, pp.1410-1413, 2010. ,
DOI : 10.1093/nar/gkl952
Germline mutations in BAP1 predispose to melanocytic tumors, Nature Genetics, vol.43, issue.10, pp.1018-1039, 2011. ,
DOI : 10.1186/gb-2007-8-11-r232
Pigmentary characteristics and moles in relation to melanoma risk, International Journal of Cancer, vol.46, issue.1, pp.144-153, 2005. ,
DOI : 10.1038/bjc.1996.302
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.21001/pdf
The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity, Dermatol Online J, vol.5, p.3, 1999. ,
Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, British Journal of Dermatology, vol.141, pp.669-76, 2008. ,
DOI : 10.1001/archderm.137.10.1343
Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for the diagnosis of melanoma, British Journal of Dermatology, vol.6, issue.Suppl. 1, pp.591-604, 2009. ,
DOI : 10.7326/0003-4819-120-8-199404150-00008
Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society, Journal of the European Academy of Dermatology and Venereology, vol.36, issue.7, pp.805-819, 2013. ,
DOI : 10.1016/S0190-9622(97)80324-6
The classification of malignant melanoma and its histologic reporting, Cancer, vol.18, issue.6, pp.1446-57, 1973. ,
DOI : 10.1016/S0031-3025(16)39458-2
Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls, Future Oncology, vol.22, issue.7, pp.1163-75, 2010. ,
DOI : 10.1038/modpathol.2009.116
Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification, In Vivo, vol.28, pp.1005-1016, 2014. ,
Melanoma in situ, Journal of the American Academy of Dermatology, vol.73, issue.2, pp.181-90, 2015. ,
DOI : 10.1016/j.jaad.2015.04.014
Acral Lentiginous Melanoma, Cancer Treat Res, vol.167, pp.321-330, 2016. ,
DOI : 10.1007/978-3-319-22539-5_14
Primary mucosal melanoma, Journal of the American Academy of Dermatology, vol.56, issue.5, pp.828-862, 2007. ,
DOI : 10.1016/j.jaad.2006.06.017
Desmoplastic melanoma: A review, Journal of the American Academy of Dermatology, vol.68, issue.5, pp.825-858, 2013. ,
DOI : 10.1016/j.jaad.2012.10.041
Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009. ,
DOI : 10.1200/JCO.2009.23.4799
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035/pdf
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview, J Exp Clin Cancer Res CR, vol.19, pp.21-34, 2000. ,
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study, Journal of Clinical Oncology, vol.22, issue.6, pp.1118-1143, 2004. ,
DOI : 10.1200/JCO.2004.04.165
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma, Journal of Clinical Oncology, vol.18, issue.1, pp.158-66, 2000. ,
DOI : 10.1200/JCO.2000.18.1.158
Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains, European Journal of Immunology, vol.13, issue.12, pp.1901-1906, 1988. ,
DOI : 10.1002/eji.1830181206
CTLA-4: a negative regulator of autoimmune disease, Journal of Experimental Medicine, vol.184, issue.2, pp.783-791, 1996. ,
DOI : 10.1084/jem.184.2.783
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proceedings of the National Academy of Sciences, vol.163, issue.14, pp.8372-8379, 2003. ,
DOI : 10.1073/pnas.0830997100
URL : http://www.pnas.org/content/100/14/8372.full.pdf
CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301], Journal of Experimental Medicine, vol.183, issue.6, pp.2541-50, 1996. ,
DOI : 10.1084/jem.183.6.2541
URL : http://jem.rupress.org/content/jem/183/6/2541.full.pdf
Checkpoint blocking antibodies in cancer immunotherapy, FEBS Letters, vol.31, issue.2, pp.368-76, 2014. ,
DOI : 10.1056/NEJMe1205943
URL : http://onlinelibrary.wiley.com/doi/10.1016/j.febslet.2013.10.015/pdf
PD-1 as a potential target in cancer therapy, Cancer Medicine, vol.16, issue.Suppl., pp.662-73, 2013. ,
DOI : 10.1016/j.molmed.2010.02.001
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, International Immunology, vol.19, issue.10, pp.1223-1257, 2007. ,
DOI : 10.1093/intimm/dxm091
URL : https://academic.oup.com/intimm/article-pdf/19/10/1223/2230147/dxm091.pdf
T Cells, Cancer Research, vol.64, issue.3, pp.1140-1145, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3259
URL : https://hal.archives-ouvertes.fr/inserm-01408787
Occurrence of Subacute Cutaneous Lupus Erythematosus After Treatment With Systemic Fluorouracil, Journal of Clinical Oncology, vol.29, issue.20, pp.613-615, 2011. ,
DOI : 10.1200/JCO.2011.35.0686
Enhancement of Antitumor Immunity by CTLA-4 Blockade, Science, vol.271, issue.5256, pp.1734-1740, 1996. ,
DOI : 10.1126/science.271.5256.1734
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2543, 2011. ,
DOI : 10.1056/NEJMoa1104621
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma, Clinical Cancer Research, vol.18, issue.7, pp.2039-2086, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-1823
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010. ,
DOI : 10.1056/NEJMoa1003466
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/pdf
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, issue.9948, pp.1109-1126, 2014. ,
DOI : 10.1016/S0140-6736(14)60958-2
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma, JAMA, vol.315, issue.15, pp.1600-1609, 2016. ,
DOI : 10.1001/jama.2016.4059
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, The Lancet Oncology, vol.16, issue.8, pp.908-926, 2015. ,
DOI : 10.1016/S1470-2045(15)00083-2
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab, Cancer Immunology Research, vol.4, issue.4, pp.345-53, 2016. ,
DOI : 10.1158/2326-6066.CIR-15-0193
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015. ,
DOI : 10.1016/S1470-2045(15)70076-8
Wild-Type Advanced Melanoma, JAMA Oncology, vol.1, issue.4 ,
DOI : 10.1001/jamaoncol.2015.1184
Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015. ,
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00872683
CTLA-4 and PD-1 Pathways, American Journal of Clinical Oncology, vol.39, issue.1, pp.98-106, 2016. ,
DOI : 10.1097/COC.0000000000000239
URL : http://doi.org/10.1097/coc.0000000000000239
Stepping up melanocytes to the challenge of UV exposure, Pigment Cell & Melanoma Research, vol.90, issue.7, pp.171-86, 2010. ,
DOI : 10.1073/pnas.90.9.4216
How are proliferation and differentiation of melanocytes regulated?, Pigment Cell & Melanoma Research, vol.33, issue.Suppl. 8, pp.462-78, 2011. ,
DOI : 10.1038/ng1087
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1755-148X.2011.00845.x/pdf
MAP kinase signaling and inhibition in melanoma, Oncogene, vol.18, issue.19, pp.2373-2382, 2013. ,
DOI : 10.1158/1078-0432.CCR-11-2479
Raf Family Kinases: Old Dogs Have Learned New Tricks, Genes & Cancer, vol.2, issue.3, pp.232-60, 2011. ,
DOI : 10.1177/1947601911407323
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128629/pdf
Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes, The EMBO Journal, vol.19, issue.12, pp.2900-2910, 2000. ,
DOI : 10.1093/emboj/19.12.2900
Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002. ,
DOI : 10.1016/S0960-9822(97)70094-0
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma, Clinical Cancer Research, vol.18, issue.12, pp.3242-3251, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-0052
Ras, Raf, and MAP Kinase in Melanoma, Advances In Anatomic Pathology, vol.20, issue.4, pp.217-243, 2013. ,
DOI : 10.1097/PAP.0b013e3182976c94
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, vol.26, issue.7315, pp.596-605, 2010. ,
DOI : 10.1200/JCO.2008.20.3745
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010. ,
DOI : 10.1056/NEJMoa1002011
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-65, 2012. ,
DOI : 10.1016/S0140-6736(12)60868-X
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014. ,
DOI : 10.1016/S1470-2045(14)70012-9
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM), J Clin Oncol, vol.31, pp.9013-9013, 2013. ,
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma, Cancer Chemotherapy and Pharmacology, vol.26, issue.1, pp.103-114, 2014. ,
DOI : 10.1016/j.ejps.2005.05.010
Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-721, 2012. ,
DOI : 10.1056/NEJMoa1112302
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724515/pdf
Clinical Pharmacokinetics of Vemurafenib, Clinical Pharmacokinetics, vol.11, issue.1, pp.1033-1076, 2017. ,
DOI : 10.1007/s11523-015-0375-8
Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, issue.17, pp.4449-58, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0887
URL : http://clincancerres.aacrjournals.org/content/clincanres/20/17/4449.full.pdf
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma, Pharmacology Research & Perspectives, vol.30, issue.Suppl., p.113, 2015. ,
DOI : 10.1200/JCO.2011.41.1660
Population pharmacokinetics and exposure???response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma, Cancer Chemotherapy and Pharmacology, vol.45, issue.2, pp.807-824, 2016. ,
DOI : 10.1016/j.ejca.2008.10.026
Vemurafenib: the first drug approved for BRAF-mutant cancer, Nature Reviews Drug Discovery, vol.61, issue.11, pp.873-86, 2012. ,
DOI : 10.1038/383181a0
Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation, Drug Metabolism and Disposition, vol.41, issue.12, pp.2215-2239, 2013. ,
DOI : 10.1124/dmd.113.053785
Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers, Xenobiotica, vol.66, issue.4, pp.352-68, 2014. ,
DOI : 10.1128/AEM.66.6.2336-2342.2000
Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis, Pigment Cell & Melanoma Research, vol.372, issue.1, pp.68-71, 2017. ,
DOI : 10.1056/NEJMoa1412690
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.26, pp.3205-3216, 2013. ,
DOI : 10.1200/JCO.2013.49.8691
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, British Journal of Dermatology, vol.230, issue.Suppl., pp.1153-60, 2012. ,
DOI : 10.1006/bbrc.1996.5891
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions, International Journal of Dermatology, vol.163, issue.3, pp.376-84, 2014. ,
DOI : 10.1111/j.1365-2133.2010.09751.x
mutation, Future Oncology, vol.29, issue.5, pp.499-507, 2012. ,
DOI : 10.1056/NEJMoa1105358
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-336, 2013. ,
DOI : 10.1634/theoncologist.2012-0333
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, The Lancet Oncology, vol.15, issue.4, pp.436-480, 2014. ,
DOI : 10.1016/S1470-2045(14)70051-8
Profile of vemurafenib-induced severe skin toxicities, Journal of the European Academy of Dermatology and Venereology, vol.115, issue.2, pp.250-257, 2016. ,
DOI : 10.1002/cncr.24088
N??crolyse ??pidermique toxique au vemurafenib, Annales de Dermatologie et de V??n??r??ologie, vol.141, issue.3, pp.215-223, 2014. ,
DOI : 10.1016/j.annder.2013.10.054
Interplay Between Membrane Lipid Peroxidation and Photoproduct Formation in the Ultraviolet A-Induced Phototoxicity of Vemurafenib in Skin Keratinocytes, Toxicological Sciences, vol.154, issue.2, pp.289-95, 2016. ,
DOI : 10.1093/toxsci/kfw159
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive, Eur J Dermatol EJD, vol.25, pp.452-458, 2015. ,
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Annals of Oncology, vol.24, issue.6, pp.1691-1698, 2013. ,
DOI : 10.1093/annonc/mdt015
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52??weeks, British Journal of Dermatology, vol.134, issue.15 Suppl., pp.239-282, 2015. ,
DOI : 10.1038/jid.2013.462
Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, New England Journal of Medicine, vol.366, issue.3, pp.207-222, 2012. ,
DOI : 10.1056/NEJMoa1105358
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724537/pdf
Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors, Journal of Clinical Oncology, vol.30, issue.3, pp.316-337, 2012. ,
DOI : 10.1200/JCO.2011.36.7680
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF, Cell, vol.140, issue.2, pp.209-230, 2010. ,
DOI : 10.1016/j.cell.2009.12.040
URL : https://doi.org/10.1016/j.cell.2009.12.040
A Landscape of Driver Mutations in Melanoma, Cell, vol.150, issue.2, pp.251-63, 2012. ,
DOI : 10.1016/j.cell.2012.06.024
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, vol.6, issue.7287, pp.427-457, 2010. ,
DOI : 10.1016/S1359-6349(09)72036-1
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178447/pdf
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.66, issue.7326, pp.973-980, 2010. ,
DOI : 10.1158/0008-5472.CAN-05-4227
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143360/pdf
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, issue.6, pp.683-95, 2010. ,
DOI : 10.1016/j.ccr.2010.11.023
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.7, issue.7436, pp.251-256, 2013. ,
DOI : 10.1097/JTO.0b013e31823c5aee
Melanoma whole-exome sequencing identifies V600E B- RAF amplification-mediated acquired B-RAF inhibitor resistance, Nat Commun, vol.3, p.1727, 2012. ,
DOI : 10.1038/ncomms1727
URL : http://www.nature.com/articles/ncomms1727.pdf
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.21, issue.7326, pp.968-72, 2010. ,
DOI : 10.1038/sj.onc.1205550
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058384/pdf
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.11, issue.7377, pp.387-90, 2011. ,
DOI : 10.1002/cyto.990110707
Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors, Pigment Cell & Melanoma Research, vol.487, issue.2, pp.253-62, 2014. ,
DOI : 10.1038/nature11249
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain, Pigment Cell & Melanoma Research, vol.2, issue.1, pp.124-157, 2014. ,
DOI : 10.1126/scitranslmed.3000758
M??canismes de r??sistance aux inhibiteurs de BRAF, Annales de Dermatologie et de V??n??r??ologie, vol.141, issue.11, pp.671-81, 2014. ,
DOI : 10.1016/j.annder.2014.06.021
Tumor Suppressor Pathway, Journal of Clinical Oncology, vol.22, issue.14, pp.2954-63, 2004. ,
DOI : 10.1200/JCO.2004.02.141
BrafV600E cooperates with Pten loss to induce metastatic melanoma, Nature Genetics, vol.17, issue.5, pp.544-52, 2009. ,
DOI : 10.1038/75973
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705918/pdf
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression, Cancer Research, vol.71, issue.7, pp.2750-60, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-2954
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, vol.1, issue.7408, pp.505-514, 2012. ,
DOI : 10.1158/2159-8290.CD-11-0175
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724525/pdf
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas, Molecular Cancer Therapeutics, vol.7, issue.9, pp.2876-83, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0431
URL : http://mct.aacrjournals.org/content/molcanther/7/9/2876.full.pdf
in Melanomagenesis, Cancer Discovery, vol.3, issue.3, pp.338-387, 2013. ,
DOI : 10.1158/2159-8290.CD-12-0313
-Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014. ,
DOI : 10.1056/NEJMoa1408868
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1877-88, 2014. ,
DOI : 10.1056/NEJMoa1406037
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, issue.9992, pp.444-51, 2015. ,
DOI : 10.1016/S0140-6736(15)60898-4
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma, Journal of the American Academy of Dermatology, vol.71, issue.6, pp.1102-1109, 2014. ,
DOI : 10.1016/j.jaad.2014.09.002
-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor, Journal of Clinical Oncology, vol.31, issue.4, pp.482-491, 2013. ,
DOI : 10.1200/JCO.2012.43.5966
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878037/pdf
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma, Nature Communications, vol.129, p.5694, 2014. ,
DOI : 10.1038/jid.2009.5
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy, Cancer Discovery, vol.4, issue.1, pp.80-93, 2014. ,
DOI : 10.1158/2159-8290.CD-13-0642
URL : http://cancerdiscovery.aacrjournals.org/content/candisc/4/1/80.full.pdf
KIT as a Therapeutic Target in Metastatic Melanoma, JAMA, vol.305, issue.22, pp.2327-2361, 2011. ,
DOI : 10.1001/jama.2011.746
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06), The Oncologist, vol.20, issue.11, pp.1312-1321, 2015. ,
DOI : 10.1634/theoncologist.2015-0161
Mutation or Amplification, Journal of Clinical Oncology, vol.29, issue.21, pp.2904-2913, 2011. ,
DOI : 10.1200/JCO.2010.33.9275
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network, Journal of Investigative Dermatology, 2017. ,
DOI : 10.1016/j.jid.2017.07.839
mutation frequencies in relation to histogenetic subclass and body site, Molecular Oncology, vol.19, issue.4, pp.395-405, 2008. ,
DOI : 10.1093/emboj/19.20.5429
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543839/pdf
Treatment of NRAS-Mutant Melanoma, Current Treatment Options in Oncology, vol.70, issue.9, p.15, 2015. ,
DOI : 10.1158/0008-5472.CAN-10-0118
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830486/pdf
Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, issue.4, pp.435-480, 2017. ,
DOI : 10.1016/S1470-2045(17)30180-8
Management of Cancer in the Older Person: A Practical Approach, The Oncologist, vol.5, issue.3, pp.224-261, 2000. ,
DOI : 10.1634/theoncologist.5-3-224
Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study, PLoS ONE, vol.49, issue.12, 2014. ,
DOI : 10.1371/journal.pone.0115060.s002
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non???Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study, Journal of Clinical Oncology, vol.34, issue.13, pp.1476-83, 2016. ,
DOI : 10.1200/JCO.2015.63.5839
URL : https://hal.archives-ouvertes.fr/hal-01282337
Comprehensive Geriatric Assessment for Older Patients With Cancer, Journal of Clinical Oncology, vol.25, issue.14, pp.1824-1855, 2007. ,
DOI : 10.1200/JCO.2007.10.6559
Adherence and health care costs, Risk Manag Healthc Policy, vol.7, pp.35-44, 2014. ,
Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination, Clinical Cancer Research, vol.12, issue.7, pp.2141-2150, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1798
Targeted therapy and elderly people: A review, European Journal of Cancer, vol.69 ,
DOI : 10.1016/j.ejca.2016.10.005
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer, Oncology Reports, vol.28, pp.721-728, 2012. ,
DOI : 10.3892/or.2012.1824
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer, Lung Cancer, vol.86, issue.2, pp.201-207, 2014. ,
DOI : 10.1016/j.lungcan.2014.09.015
Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802), Anticancer Res, vol.36, pp.2881-2888, 2016. ,
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-smallcell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study ,
Gefitinib Versus Vinorelbine in Chemotherapy-Na??ve Elderly Patients With Advanced Non???Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study, Journal of Clinical Oncology, vol.26, issue.26, pp.4253-60, 2008. ,
DOI : 10.1200/JCO.2007.15.0672
First-line gefitinib treatment in elderly patients (aged ???75??years) with non-small cell lung cancer harboring EGFR mutations, Cancer Chemotherapy and Pharmacology, vol.98, issue.Suppl 7, pp.761-770, 2015. ,
DOI : 10.1111/j.1349-7006.2007.00607.x
Recent advances in targeted advanced lung cancer therapy in the elderly, Expert Review of Anticancer Therapy, vol.36, issue.6, pp.787-97, 2017. ,
DOI : 10.1007/s10238-017-0460-7
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma, British Journal of Cancer, vol.33, issue.5, pp.1125-1157, 2014. ,
DOI : 10.1093/annonc/mdq070
Safety and activity of sunitinib in elderly patients (???70 years) with metastatic renal cell carcinoma: a multicenter study, Annals of Oncology, vol.24, issue.2, pp.336-378, 2013. ,
DOI : 10.1093/annonc/mds431
Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis, Clinical Genitourinary Cancer, vol.12, issue.3, pp.182-191, 2014. ,
DOI : 10.1016/j.clgc.2013.11.005
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial, JNCI Journal of the National Cancer Institute, vol.100, issue.20, pp.1454-63, 2008. ,
DOI : 10.1093/jnci/djn319
Advanced kidney cancer: treating the elderly, Expert Review of Anticancer Therapy, vol.69, issue.15, pp.1389-98, 2013. ,
DOI : 10.1056/NEJMoa066838
Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial, European Urology, vol.61, issue.4, pp.826-859, 2012. ,
DOI : 10.1016/j.eururo.2011.12.057
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party, Haematologica, vol.92, issue.1, pp.101-106, 2007. ,
DOI : 10.3324/haematol.10239
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia, Cancer, vol.11, issue.6, pp.1105-1118, 2003. ,
DOI : 10.1002/cncr.11629
???Real-life??? results of front-line treatment with Imatinib in older patients (???65 years) with newly diagnosed chronic myelogenous leukemia, Leukemia Research, vol.34, issue.11, pp.1472-1477, 2010. ,
DOI : 10.1016/j.leukres.2010.07.001
Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients, Hematology, vol.25, issue.3, pp.133-139, 2008. ,
DOI : 10.1016/j.blre.2005.01.008
Treatment of advanced gastrointestinal stromal tumors in patients over 75??years old: clinical and pharmacological implications, Targeted Oncology, vol.63, issue.4, pp.295-300, 2013. ,
DOI : 10.1093/gerona/63.7.724
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study, Oncology, vol.78, issue.5-6, pp.329-368, 2010. ,
DOI : 10.1159/000320222
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma, Cancer, vol.52, issue.1, pp.124-154, 2016. ,
DOI : 10.1097/MLR.0b013e31825a8c22
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.29728/pdf
Distinctive Features of Melanoma and Its Management in Elderly Patients, JAMA Dermatology, vol.149, issue.10, pp.1150-1157, 2013. ,
DOI : 10.1001/jamadermatol.2013.706
The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France, British Journal of Dermatology, vol.144, issue.Suppl. 1, pp.1351-1360, 2012. ,
DOI : 10.1001/archderm.144.5.629
URL : https://hal.archives-ouvertes.fr/hal-00727660
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts, Journal of Translational Medicine, vol.77, issue.1, pp.10-1186, 2016. ,
DOI : 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
Place des traitements innovants du m??lanome m??tastatique chez le sujet ??g??, Annales de Dermatologie et de V??n??r??ologie, vol.142, issue.10, pp.549-56, 2015. ,
DOI : 10.1016/j.annder.2015.03.022
Checkpoint inhibition and melanoma: Considerations in treating the older adult, Journal of Geriatric Oncology, vol.8, issue.4, pp.237-278, 2017. ,
DOI : 10.1016/j.jgo.2017.04.003
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treatment Reviews, vol.45, pp.30-37, 2016. ,
DOI : 10.1016/j.ctrv.2016.02.006
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, Journal of Experimental & Clinical Cancer Research, vol.33, issue.1, p.30, 2014. ,
DOI : 10.1189/jlb.0108023
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, The Lancet Oncology, vol.17, issue.11, pp.1558-68, 2016. ,
DOI : 10.1016/S1470-2045(16)30366-7
Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+), J Clin Oncol, vol.34, pp.10009-10009, 2016. ,
Age as a prognostic factor in the malignant melanoma population, Annals of Surgical Oncology, vol.218, issue.6, pp.487-94, 1994. ,
DOI : 10.1093/ajcp/74.3.247
Correlation Between Prognostic Factors and Increasing Age in Melanoma, Annals of Surgical Oncology, vol.86, issue.(9 Suppl), pp.259-64, 2004. ,
DOI : 10.1245/ASO.2004.04.015
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients, Clinica Chimica Acta, vol.470, pp.8-13, 2017. ,
DOI : 10.1016/j.cca.2017.04.009
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma, Clinica Chimica Acta, vol.472, pp.26-35, 2017. ,
DOI : 10.1016/j.cca.2017.07.012
Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma, Melanoma Research, vol.24, issue.5, pp.468-74, 2014. ,
DOI : 10.1097/CMR.0000000000000110
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015. ,
DOI : 10.1056/NEJMoa1412690
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem, Current Oncology Reports, vol.365, issue.15, pp.249-59, 2013. ,
DOI : 10.1074/jbc.273.34.21730
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.50, issue.7287, pp.431-436, 2010. ,
DOI : 10.1128/MCB.14.12.8212
Medication Non-Adherence in the Elderly, Drugs & Aging, vol.15, issue.12, pp.793-811, 2004. ,
DOI : 10.2165/00002512-200421120-00004
Medication Adherence in Older Adults With Cognitive Impairment: A Systematic Evidence-Based Review, The American Journal of Geriatric Pharmacotherapy, vol.10, issue.3, pp.165-77, 2012. ,
DOI : 10.1016/j.amjopharm.2012.04.004
Polypharmacy and potentially inappropriate medication use in geriatric oncology, Journal of Geriatric Oncology, vol.7, issue.5, pp.346-53, 2016. ,
DOI : 10.1016/j.jgo.2016.07.010
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037024/pdf
A Systematic Review of Adherence to Oral Antineoplastic Therapies, The Oncologist, vol.21, issue.3, pp.354-76, 2016. ,
DOI : 10.1634/theoncologist.2015-0405
Determinants of patient adherence: a review of systematic reviews, Frontiers in Pharmacology, vol.4, p.91, 2013. ,
DOI : 10.3389/fphar.2013.00091
Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review, J Clin Oncol, vol.31, pp.20596-20596, 2013. ,
Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors, Cancer Nursing, vol.39, issue.2, pp.153-62, 2016. ,
DOI : 10.1097/NCC.0000000000000250
Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study, Cancer Prevention Research, vol.7, issue.1, pp.161-169, 2014. ,
DOI : 10.1158/1940-6207.CAPR-13-0165
Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations, Cancer Treatment Reviews, vol.57, pp.58-66, 2017. ,
DOI : 10.1016/j.ctrv.2017.05.002
Interventions for enhancing medication adherence, Cochrane Database Syst Rev, vol.288, issue.3, p.11, 2008. ,
DOI : 10.1161/01.HYP.4.3.415
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors, Journal of Pharmaceutical Sciences, vol.102, issue.9, pp.3100-3109, 2013. ,
DOI : 10.1002/jps.23519
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites, The Journal of Clinical Pharmacology, vol.12, issue.Suppl. 1, pp.696-706, 2014. ,
DOI : 10.2174/138920011796504527
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications, British Journal of Clinical Pharmacology, vol.20, issue.Suppl 8, pp.6-14, 2004. ,
DOI : 10.1111/j.1365-2125.1985.tb05041.x
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2125.2003.02007.x/pdf
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma, Targeted Oncology, vol.25, issue.1, pp.59-69, 2016. ,
DOI : 10.1093/annonc/mdt587
Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer, Cancer Biomarkers, vol.27, issue.3, pp.425-458, 2016. ,
DOI : 10.1200/JCO.2008.19.8440
Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study, BMC Cancer, vol.37, issue.4, p.407, 2013. ,
DOI : 10.3109/02770900009055457
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care, Supportive Care in Cancer, vol.8, issue.Suppl 1, pp.1009-1027, 2011. ,
DOI : 10.1016/j.ejon.2004.06.008
A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance, Health Expectations, vol.50, issue.3, pp.235-280, 2004. ,
DOI : 10.1053/seiz.1998.0232
Interventions to improve adherence to selfadministered medications for chronic diseases in the United States: a systematic review ,
Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma, Clinical Journal of Oncology Nursing, vol.18, issue.6, pp.694-700, 2014. ,
DOI : 10.1188/14.CJON.694-700
Les infirmi??res cliniciennes am??liorent la gestion des toxicit??s des patients trait??s par soraf??nib pour carcinome h??patocellulaire, Bulletin du Cancer, vol.103, issue.11, pp.941-949, 2016. ,
DOI : 10.1016/j.bulcan.2016.09.017
A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients, Journal of Pharmaceutical and Biomedical Analysis, vol.97, pp.29-32, 2014. ,
DOI : 10.1016/j.jpba.2014.04.014
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib, Br J Clin Pharmacol, 2017. ,
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial, Cancer Chemotherapy and Pharmacology, vol.71, issue.1, pp.1307-1326, 2014. ,
DOI : 10.1007/s00280-012-1998-4
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma, Clinical Cancer Research, vol.19, issue.5, pp.1225-1256, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-1630
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma, Clinical Cancer Research, vol.18, issue.5, pp.1386-94, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2479
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/5/1386.full.pdf
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab, Pigment Cell & Melanoma Research, vol.28, issue.5, pp.611-613, 2015. ,
DOI : 10.1111/pcmr.12383
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J Clin Oncol, vol.33, pp.3003-3003, 2015. ,
Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study, J Clin Oncol, vol.34, pp.3014-3014, 2016. ,
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors, Cancer, vol.13, issue.suppl, pp.1695-701, 2014. ,
DOI : 10.1016/S1470-2045(12)70431-X
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program, Cancer Investigation, vol.11, issue.6, pp.144-153, 2014. ,
DOI : 10.1200/JCO.2009.23.4799